-
NMPA issued the Announcement on Enabling the Pharmaceutical Business Application System
2019-12-31
NMPA has integrated the development of a drug business application system to this end,covering the certificates for drug export sales,APIs exporting to EU drug substance,import and export of narcotic drugs and psychotropic substances,and the initial import of medicinal materials,etc.
-
The State Council Executive Meeting Passed the Regulation for Supervision of Cosmetics (Draft)
2020-01-06
On January 3, 2020, Premier Li Keqiang presided over an executive meeting of the State Council. In the meeting, the Regulation for Supervision of Cosmetics (Draft) was approved.
-
NMPA Issued the Administrative Measures for Key Laboratories of NMPA
2020-01-06
NMPA has organized the formulation of and released on January 6,2020 the Administrative Measures for Key Laboratories of NMPA.
-
Provisions for Medical Device Adverse Event Monitoring and Re-evaluation
2019-12-16
The Provisions for Medical Device Adverse Event Monitoring and Re-evaluation, approved by the State Administration for Market Regulation and the National Health Commission, is hereby promulgatedand shall be put into force as of January 1, 2019.
-
Provisions for Medical Device Standards (Decree No. 33 of China Food and Drug Administration)
2019-12-16
The Provisions for Medical Device Standards adopted at the executive meeting of China Food and Drug Administration on February 21, 2017, is hereby promulgated and shall be effective as of July 1, 2017.
-
Decision of CFDA on Adjusting Approval Procedures for Certain Administrative Examination and Approval Items of Medical Devices (Decree No. 32 of China Food and Drug Administration)
2019-12-16
The Decision of CFDA on Adjusting Approval Procedures for Certain Administrative Examination and Approval Items of Medical Devices adopted at the executive meeting of China Food and Drug Administration on February 21, 2017, is hereby promulgated and shall be effective as of July 1, 2017.